Shionogi & Co FCF yield
Что обозначает FCF yield в Shionogi & Co?
FCF yield Shionogi & Co., Ltd. является 3.85%
Какое определение для FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield компаний в Health Care сектор на OTC по сравнению с Shionogi & Co
Что делает Shionogi & Co?
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Компании с fcf yield похож на Shionogi & Co
- Megaport имеет FCF yield из 3.83%
- Air Liquide SA имеет FCF yield из 3.83%
- The Original BARK имеет FCF yield из 3.84%
- Dun & Bradstreet имеет FCF yield из 3.84%
- Alpha Markets Consulting plc имеет FCF yield из 3.84%
- Enbridge имеет FCF yield из 3.85%
- Shionogi & Co имеет FCF yield из 3.85%
- PharmaSGP SE имеет FCF yield из 3.85%
- JFrog Ltd имеет FCF yield из 3.85%
- China Foods имеет FCF yield из 3.85%
- GRC International plc имеет FCF yield из 3.85%
- Ingenico SA имеет FCF yield из 3.85%
- Analogue Ltd имеет FCF yield из 3.85%